InfraRX Down Ahead of Next Quarterly Report

InflaRx N.V. (NASDAQ: IFRX) opened Friday in the red. The German-based biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced that it will ...

InflaRx to Report First Quarter 2026 Results on May 7, 2026

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and ...
rarediseaseadvisor

Controversies in AAV Management and Complement-Targeted Precision Therapy

(Getty) Recent developments in complement biology and targeted therapies represent important advancements in addressing some of the unresolved challenges in AAV. Despite major therapeutic advances, ...

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan ...
Yahoo Finance

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

JENA, Germany, March 18, 2026 (GLOBE NEWSWIRE)-- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...
SciELO

C5aR antagonist inhibits LPS-induced inflammation in human gingival fibroblasts via NF-κB and MAPK signaling pathways

Objective Abnormal complement activation is associated with periodontitis. W54011 is a novel non-peptide C5aR antagonist (C5aRA) that exhibits favorable anti-inflammatory effects in various ...
ALZFORUM

Brain Injury Swells Ranks of Complement-Primed Microglia

Scientists have spotted a new variety of riled-up microglia that drives swelling in the human brain. In the November 18 Neuron, researchers from China led by Haixiao Liu, Shunnan Ge, and Yan Qu at ...

InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company") ...

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the ...
Healio

Avacopan yields strong safety profile in ANCA-associated vasculitis

Please provide your email address to receive an email when new articles are posted on . Avacopan was associated with fewer serious adverse events than controls in ANCA-associated vasculitis. Data from ...
The American Journal of Managed Care

Zilucoplan’s Edge in Complement Inhibition in Myasthenia Gravis: Miriam Freimer, MD

Mirima Freimer, MD, delves into potential reasons behind the longer-term efficacy of zilucoplan and also speaks to the treatment’s safety profile. Freimer was an author on 5 abstracts presented at the ...